137 related articles for article (PubMed ID: 31580800)
1. Multitarget Therapy: An Effective and Safe Therapeutic Regimen for Lupus Nephritis.
Zhou T; Zhang X; Lin W; Lin S
J Pharm Pharm Sci; 2019; 22(1):365-375. PubMed ID: 31580800
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis.
Zhou T; Lin S; Yang S; Lin W
Drug Des Devel Ther; 2019; 13():857-869. PubMed ID: 30880918
[TBL] [Abstract][Full Text] [Related]
3. Multitarget therapy versus intravenous cyclophosphamide in the induction treatment of lupus nephritis: a metaanalysis of randomized controlled trials.
Deng J; Luo L; Zhu L; Xie H; xie H
Turk J Med Sci; 2018 Oct; 48(5):901-910. PubMed ID: 30384552
[TBL] [Abstract][Full Text] [Related]
4. Multitarget therapy versus monotherapy as induction treatment for lupus nephritis: A meta-analysis of randomized controlled trials.
Lee YH; Song GG
Lupus; 2022 Oct; 31(12):1468-1476. PubMed ID: 35986446
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
Choi CB; Won S; Bae SC
Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis.
Deng J; Huo D; Wu Q; Yang Z; Liao Y
Tohoku J Exp Med; 2012 Aug; 227(4):281-8. PubMed ID: 22820853
[TBL] [Abstract][Full Text] [Related]
7. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial.
Liu Z; Zhang H; Liu Z; Xing C; Fu P; Ni Z; Chen J; Lin H; Liu F; He Y; He Y; Miao L; Chen N; Li Y; Gu Y; Shi W; Hu W; Liu Z; Bao H; Zeng C; Zhou M
Ann Intern Med; 2015 Jan; 162(1):18-26. PubMed ID: 25383558
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus use in lupus nephritis: A systematic review and meta-analysis.
Hannah J; Casian A; D'Cruz D
Autoimmun Rev; 2016 Jan; 15(1):93-101. PubMed ID: 26427983
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H
Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792
[TBL] [Abstract][Full Text] [Related]
10. Treatment for lupus nephritis.
Henderson L; Masson P; Craig JC; Flanc RS; Roberts MA; Strippoli GF; Webster AC
Cochrane Database Syst Rev; 2012 Dec; 12():CD002922. PubMed ID: 23235592
[TBL] [Abstract][Full Text] [Related]
11. Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial.
Zhang M; Qi C; Zha Y; Chen J; Luo P; Wang L; Sun Z; Wan J; Xing C; Wang S; Jiang G; Sun M; Chen Q; Chen J; Li D; Guan T; Ni Z
Clin Rheumatol; 2019 Mar; 38(3):859-867. PubMed ID: 30426311
[TBL] [Abstract][Full Text] [Related]
12. Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study.
Mehra S; Usdadiya JB; Jain VK; Misra DP; Negi VS
Rheumatol Int; 2018 Apr; 38(4):557-568. PubMed ID: 29450636
[TBL] [Abstract][Full Text] [Related]
13. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Mok CC
Nephrol Dial Transplant; 2016 Oct; 31(10):1561-6. PubMed ID: 27591327
[TBL] [Abstract][Full Text] [Related]
14. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Lupus; 2015 Dec; 24(14):1520-8. PubMed ID: 26162684
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
[TBL] [Abstract][Full Text] [Related]
16. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis.
Lee YH; Woo JH; Choi SJ; Ji JD; Song GG
Lupus; 2010 May; 19(6):703-10. PubMed ID: 20064907
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan.
Sakai R; Kurasawa T; Nishi E; Kondo T; Okada Y; Shibata A; Nishimura K; Chino K; Okuyama A; Takei H; Nagasawa H; Amano K
Lupus; 2018 Feb; 27(2):273-282. PubMed ID: 28683654
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Different Uses of Cyclophosphamide in Lupus Nephritis: A Meta-Analysis of Randomized Controlled Trials.
Li Y; Xu S; Xu G
Endocr Metab Immune Disord Drug Targets; 2020; 20(5):687-702. PubMed ID: 31702519
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression.
Mak A; Cheak AA; Tan JY; Su HC; Ho RC; Lau CS
Rheumatology (Oxford); 2009 Aug; 48(8):944-52. PubMed ID: 19494179
[TBL] [Abstract][Full Text] [Related]
20. Rituximab treatment for lupus nephritis: A systematic review.
Yuan Z; Xie Q; Wu X; Tan B; Zhang X
Clin Invest Med; 2020 Jun; 43(2):E47-54. PubMed ID: 32593276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
